Hemiparkinsonism

Hemiparkinsonism

Introduction

Hemiparkinsonism is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.

Overview

Hemiparkinsonism is a rare neurological syndrome characterized by Parkinsonian features affecting only one side of the body (unilateral). It represents a distinct clinical entity within the spectrum of Parkinsonian disorders, typically resulting from localized damage to the substantia nigra pars compacta on one side of the brain ^[1]. [@alteration]

Unlike classic Parkinson's disease, which typically presents with bilateral symptoms, hemiparkinsonism demonstrates a lateralized pattern of motor impairment, providing important clues about its underlying etiology. [@hemiparkinsonism]

Etiology and Causes

Primary Causes

Stroke (Cerebrovascular Hemiparkinsonism)

• Lacunar infarcts in the substantia nigra
• Small vessel disease affecting unilateral dopaminergic pathways
• Ischemic damage to the nigrostriatal pathway

Brain Tumors

• Tumors compressing the substantia nigra
• Metastatic lesions affecting unilateral dopaminergic [neurons](/entities/neurons)
• Primary brain tumors in the midbrain region

Traumatic Brain Injury

• Unilateral head trauma damaging the substantia nigra
• Penetrating injuries to the midbrain

...

Hemiparkinsonism

Introduction

Hemiparkinsonism is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.

Overview

Hemiparkinsonism is a rare neurological syndrome characterized by Parkinsonian features affecting only one side of the body (unilateral). It represents a distinct clinical entity within the spectrum of Parkinsonian disorders, typically resulting from localized damage to the substantia nigra pars compacta on one side of the brain ^[1]. [@alteration]

Unlike classic Parkinson's disease, which typically presents with bilateral symptoms, hemiparkinsonism demonstrates a lateralized pattern of motor impairment, providing important clues about its underlying etiology. [@hemiparkinsonism]

Etiology and Causes

Primary Causes

Stroke (Cerebrovascular Hemiparkinsonism)

• Lacunar infarcts in the substantia nigra
• Small vessel disease affecting unilateral dopaminergic pathways
• Ischemic damage to the nigrostriatal pathway

Brain Tumors

• Tumors compressing the substantia nigra
• Metastatic lesions affecting unilateral dopaminergic [neurons](/entities/neurons)
• Primary brain tumors in the midbrain region

Traumatic Brain Injury

• Unilateral head trauma damaging the substantia nigra
• Penetrating injuries to the midbrain

Neurodegeneration

• Unilateral progression of Parkinson's disease
• Rare cases of truly unilateral Parkinsonian degeneration

Other Causes

• Infection (encephalitis affecting one side)
• Vascular malformations
• Surgical complications

Risk Factors

• History of stroke or transient ischemic attacks
• Hypertension
• Diabetes mellitus
• History of head trauma
• Occupational exposures

Pathophysiology

Neuroanatomical Basis

The characteristic unilateral symptoms result from: [@levodopa]

• Selective loss of dopaminergic neurons in the substantia nigra pars compacta on one side
• Disruption of the nigrostriatal pathway (dopaminergic projections to the striatum)
• Preservation of the contralateral nigrostriatal system

Neurochemical Changes

• Decreased dopamine in the ipsilateral striatum
• Loss of neuromelanin-containing neurons
• Reduced tyrosine hydroxylase activity
• Compensatory mechanisms in the unaffected hemisphere

Clinical Features

Motor Symptoms (Unilateral)

Resting Tremor

• Pill-rolling tremor of the fingers
• Present at rest, often improves with movement
• Typically begins in the hand

Bradykinesia

• Decreased spontaneous movement
• Slowed finger-tap movements
• Reduced arm swing on the affected side

Muscle Rigidity

• Cogwheel rigidity
• Increased tone in affected limbs
• Resistance to passive movement

Postural Instability

• May be less prominent than in idiopathic Parkinson's disease
• Usually develops later in the disease course

Non-Motor Symptoms

• Sleep disorders: REM sleep behavior disorder may occur
• Mood changes: Depression and anxiety
• Cognitive changes: Mild cognitive impairment in some cases
• Autonomic dysfunction: Less prominent than in classic PD

Pattern of Progression

• Symptoms remain lateralized in many cases
• May spread to contralateral side over time (5-10 years)
• Rate of progression varies significantly

Diagnosis

Clinical Criteria

Presence of at least two cardinal features:

• Resting tremor
• Bradykinesia
• Rigidity

2. Unilateral onset and predominance

Asymmetric DAT scan findings

Exclusion of other causes

Diagnostic Tests

• Neurological examination: Detailed assessment of lateralized symptoms
• DaTscan (FP-CIT SPECT): Shows reduced dopamine transporter binding on the affected side
• MRI brain: Rules out structural causes (stroke, tumor)
• Transcranial sonography: May show increased echogenicity of substantia nigra

Differential Diagnosis

• Classic Parkinson's disease (will become bilateral)
• Progressive supranuclear palsy
• Corticobasal degeneration
• Multiple system atrophy
• Vascular parkinsonism

Treatment

Pharmacological Therapy

Dopamine Precursors

• Levodopa/Carbidopa: Effective but may cause dyskinesias
• Response typically good but may be less dramatic than in classic PD

Dopamine Agonists

• Pramipexole, ropinirole
• May be used as first-line or adjunct therapy

MAO-B Inhibitors

• Selegiline, rasagiline
• Mild symptomatic benefit

Anticholinergics

• Trihexyphenidyl
• May help tremor-dominant cases

Surgical Interventions

• Deep Brain Stimulation (DBS): Particularly effective for tremor
• Target: Vim nucleus of thalamus or STN
• Requires careful patient selection

Rehabilitation

• Physical therapy: Maintains mobility and balance
• Occupational therapy: Adaptive strategies
• Speech therapy: If dysarthria develops

Prognosis

Disease Course

• Generally slower progression than classic Parkinson's disease
• Many patients maintain good function for years
• Eventual bilateral involvement in 30-50% of cases

Functional Outcomes

• Good response to dopaminergic therapy in most cases
• Quality of life often preserved for extended periods
• Risk of falls increases with disease progression

Epidemiology

• Rare condition representing <5% of all Parkinsonian syndromes
• More common in older adults
• Vascular etiology increasingly recognized

Research Directions

Neuroimaging Studies

• Advanced MRI techniques to characterize structural changes
• PET studies of dopamine metabolism
• Functional connectivity mapping

Biomarkers

• Development of biomarkers to predict progression
• Genetic risk factors for unilateral susceptibility
• [Parkinson's Disease](/diseases/parkinsons-disease) - Classic bilateral Parkinsonian syndrome
• [Progressive Supranuclear Palsy (PSP)](/diseases/progressive-supranuclear-palsy) - Atypical Parkinsonian syndrome
• [Corticobasal Degeneration (CBD)](/diseases/corticobasal-degeneration) - Asymmetric Parkinsonian features
• [Vascular Dementia](/diseases/vascular-dementia) - Cerebrovascular contributions to neurodegeneration

Background

The study of Hemiparkinsonism has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@dietary]

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [^6]

Additional evidence sources: [^7] [^8]

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Monoacylglycerol lipase inhibition improves motor function and reduces oxidative stress in hemiparkinsonian mice.](https://pubmed.ncbi.nlm.nih.gov/41397672/) (2026 Feb 6) - Neuroscience
• [Alteration of hippocampal parvalbumin interneurons underlies memory impairment in rat model of Parkinson's disease.](https://pubmed.ncbi.nlm.nih.gov/41640446/) (2025) - Frontiers in behavioral neuroscience
• [Hemiparkinsonism Associated with Venous Anomaly-related Basal Ganglia Calcification.](https://pubmed.ncbi.nlm.nih.gov/41535038/) (2026 Jan 15) - Internal medicine (Tokyo, Japan)
• [Levodopa exerts neuroprotective effects by suppressing microglial proinflammatory activation in a rat hemi-Parkinson's disease model.](https://pubmed.ncbi.nlm.nih.gov/41476679/) (2025 Dec) - IBRO neuroscience reports
• [Dietary Supplementation with Six Percent Blueberries (Vaccinium corymbosum L.) Attenuates Neurodegeneration and Motor Deficits in a Parkinson's Disease Model.](https://pubmed.ncbi.nlm.nih.gov/41082984/) (2025 Dec) - The Journal of nutrition

External Links

• [Hemiparkinsonism - Medscape](https://emedicine.medscape.com/article/1150269-overview)
• [Parkinsoni

References

[Unknown, Monoacylglycerol lipase inhibition improves motor function and reduces oxidative stress in hemiparkinsonian mice (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41397672/)

[Unknown, Alteration of hippocampal parvalbumin interneurons underlies memory impairment in rat model of Parkinson's disease (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41640446/)

[Unknown, Hemiparkinsonism Associated with Venous Anomaly-related Basal Ganglia Calcification (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41535038/)

[Unknown, Levodopa exerts neuroprotective effects by suppressing microglial proinflammatory activation in a rat hemi-Parkinson's disease model (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41476679/)

[Unknown, Dietary Supplementation with Six Percent Blueberries (Vaccinium corymbosum L.) Attenuates Neurodegeneration and Motor Deficits in a Parkinson's Disease Model (n.d.)](https://pubmed.ncbi.nlm.nih.gov/41082984/)